U.S. markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.86
    +0.95 (+2.12%)
     
  • Gold

    1,806.10
    +0.60 (+0.03%)
     
  • Silver

    23.39
    +0.02 (+0.10%)
     
  • EUR/USD

    1.1919
    +0.0023 (+0.19%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • GBP/USD

    1.3384
    +0.0025 (+0.19%)
     
  • USD/JPY

    104.4400
    -0.0400 (-0.04%)
     
  • BTC-USD

    18,744.34
    -296.49 (-1.56%)
     
  • CMC Crypto 200

    368.46
    -2.05 (-0.55%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

Intra-Cellular Therapies (ITCI): Strong Industry, Solid Earnings Estimate Revisions

Zacks Equity Research
·2 min read

One stock that might be an intriguing choice for investors right now is Intra-Cellular Therapies, Inc. ITCI. This is because this security in the Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Biomedical and Genetics space as it currently has a Zacks Industry Rank of 58 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Intra-Cellular Therapies is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Intra-Cellular Therapies Inc. Price and Consensus

Intra-Cellular Therapies Inc. Price and Consensus
Intra-Cellular Therapies Inc. Price and Consensus

Intra-Cellular Therapies Inc. price-consensus-chart | Intra-Cellular Therapies Inc. Quote

In fact, over the past month, current quarter estimates have narrowed from a loss of $1.02 per share to a loss of 98 cents per share, while current year estimates have narrowed from a loss of $3.71 per share to a loss of $3.56 per share. This has helped ITCI to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Intra-Cellular Therapies. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

The Hottest Tech Mega-Trend of All

               
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research